Multifunctional Nanotheranostics for Dual-Modal Imaging-Guided Precision Therapy of Nasopharyngeal Carcinoma
Molecular Pharmaceutics · 2023
DOI: 10.1021/acs.molpharmaceut.3c00491 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Qianyu Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Haikou, Hainan 570311, China. Hauptthemen laut MEDLINE: Photochemotherapy, Nasopharyngeal Neoplasms, Nanoparticles. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Hainan Province Clinical Medical Center.
Abstract (Originalsprache)
Currently, the low survival rate and poor prognosis of patients with nasopharyngeal carcinoma are ascribed to the lack of early and accurate diagnosis and resistance to radiotherapy. In parallel, the integration of imaging-guided diagnosis and precise treatment has gained much attention in the field of theranostic nanotechnology. However, constructing dual-modal imaging-guided nanotheranostics with desired imaging performance as well as great biocompatibility remains challenging. Therefore, we developed a simple but multifunctional nanotheranostic GdCPP for the early and accurate diagnosis and efficient treatment of nasopharyngeal carcinoma (NPC), which combined fluorescence imaging and magnetic resonance imaging (MRI) onto a single nanoplatform for imaging-guided subsequent photodynamic therapy (PDT). GdCPP had an appropriate particle size (81.93 ± 0.69 nm) and was highly stable, resulting in sufficient tumor accumulation, which along with massive reactive oxygen species (ROS) generation upon irradiation further significantly killed tumor cells. Moreover, GdCPP owned much stronger r1 relaxivity (9.396 mM-1 s-1) compared to clinically used Gd-DTPA (5.034 mM-1 s-1) and exhibited better T1WI MRI performance. Under dual-modal imaging-guided PDT, GdCPP achieved efficient therapeutic outcomes without causing any noticeable tissue damage. The results of in vitro and in vivo studies indicated that GdCPP may be a suitable candidate for dual-modal imaging-guided precision tumor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Haikou, Hainan 570311, China.
- Department of Radiology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
- Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan 610064, China.
- School of Food and Biological Engineering, Chengdu University, Chengdu, Sichuan 610106, China.
ORCID-Profile: Qianyu Yang, Huile Gao
Förderung
- National Natural Science Foundation of China
- Hainan Province Clinical Medical Center
Zitieren
APA
Yang, Q., Guo, Y., Zhou, Y., Song, J., Song, Y., Li, H., Gao, H., & Huang, W. (2023). Multifunctional Nanotheranostics for Dual-Modal Imaging-Guided Precision Therapy of Nasopharyngeal Carcinoma. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00491
Vancouver
Yang Q, Guo Y, Zhou Y, Song J, Song Y, Li H, et al. Multifunctional Nanotheranostics for Dual-Modal Imaging-Guided Precision Therapy of Nasopharyngeal Carcinoma. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00491
BibTeX
@article{Yang2023,
author = {Yang, Qianyu and Guo, Yingkun and Zhou, Yang and Song, Jiali and Song, Yujun and Li, Hanmei and Gao, Huile and Huang, Weiyuan},
title = {Multifunctional Nanotheranostics for Dual-Modal Imaging-Guided Precision Therapy of Nasopharyngeal Carcinoma},
journal = {Molecular Pharmaceutics},
year = {2023},
doi = {10.1021/acs.molpharmaceut.3c00491}
}
EUVIMED